Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aura Biosciences Inc (NQ: AURA )

9.600 -0.740 (-7.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 128,559
Open 10.31
Bid (Size) 3.840 (2)
Ask (Size) 14.40 (1)
Prev. Close 10.34
Today's Range 9.420 - 10.32
52wk Range 9.420 - 24.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate
 
Via Benzinga

Performance

YTD
-10.03%
-10.03%
1 Month
-6.89%
-6.89%
3 Month
-8.48%
-8.48%
6 Month
-34.43%
-34.43%
1 Year
-58.87%
-58.87%

More News

Read More
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
From Aura Biosciences, Inc.
Via Business Wire
Why Shares of Aura Biosciences Jumped This Week
Via The Motley Fool
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
Via Benzinga
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
$49.5 Million Bet On Howard Hughes? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences
Via Business Wire
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Tesla, ABB And Other Big Losers From Monday
Via Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress
From Aura Biosciences Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.